Abstract #1702

Longitudinal Evaluation of MPIO-Labeled Stem Cell Biodistribution in a GBM Model using MR Imaging & DCE-MRI at 14.1Tesla

Myriam Marianne Chaumeil¹, Christopher G. Boyd², Beatrice Gini³, Raquel Santos², Jacqueline de La Torre², Christina Ng², Huijan Yang³, Akio Iwanami³, Subramanian Sukumar¹, Tomoko Ozawa², Russel O. Pieper², Paul Mischel³, C. David James², Sabrina M. Ronen¹

¹Radiology, University of California, San Francisco, San Francisco, CA, United States; ²Neurological Surgery, University of California San Francisco, San Francisco, CA, United States; ³Pathology & Lab. Medicine, University of California Los Angeles, Los Angeles, CA, United States

In an effort to design an efficient stem cell (SCs)-based therapy product for the treatment of glioblastoma (GBM) tumors, we compared the pathotropism of two different SCs sources towards GBM tumors, human mesenchymal stem cells (hMSCs) and fetal neural stem cells (fNSCs). Using MR imaging and dynamic contrast enhanced MRI at 14.1Tesla, MPIO-labeled hMSCs and fNSCs biodistributions were characterized over a 7-day period. The tropism of both fNSCs and hMSCs was found to be comparable: both SCs types first localized at the tumor edges, in highly neovascularized regions, then in the tumor mass and also further away tracking tumor microsatellites.